FTSE 100 today: Index, pound edge higher; StanChart, Revolution Beauty jump
Paul Badawi, the President and CEO of Sight Sciences , Inc. (NASDAQ:SGHT), recently sold 24,174 shares of the company’s common stock. The medical device company, currently valued at $116.5 million, has seen its stock decline over 61% in the past six months, according to InvestingPro data. The sale, conducted on April 1, 2025, was completed at an average price of $2.303 per share, totaling approximately $55,672. This transaction was made to cover tax liabilities related to the vesting of restricted stock units. Following the sale, Badawi retains ownership of 6,010,580 shares in the company, representing substantial insider ownership despite recent stock volatility. InvestingPro analysis reveals the company maintains a strong balance sheet with more cash than debt, though it’s currently trading below its Fair Value.
In other recent news, Sight Sciences Inc. reported its fourth-quarter 2024 earnings, revealing a slight miss on both earnings per share (EPS) and revenue forecasts. The company recorded an EPS of -$0.23, just below the anticipated -$0.22, and revenue of $19.1 million, falling short of the expected $20.26 million. The revenue shortfall was primarily attributed to challenges in the Surgical Glaucoma segment, exacerbated by Medicare Local Coverage Determinations (LCDs) changes. Despite these results, Sight Sciences’ surgical glaucoma revenue showed a robust 9% year-over-year growth, contributing to a 2% overall revenue increase compared to the previous year. Analysts from Stifel revised their price target for Sight Sciences, lowering it to $4.00 from $5.00, yet maintained a Buy rating, citing potential reimbursement for TearCare as a positive catalyst. The company provided guidance for 2025, projecting revenue between $70 million and $75 million, with expectations of initial reimbursement decisions for TearCare, which could positively impact future revenue streams. Sight Sciences remains focused on achieving cash flow breakeven without additional equity capital, supported by a strong balance sheet. The company anticipates that the impact of the LCD changes will be fully realized by the end of 2025, and it sees opportunities in the standalone MIGS market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.